Literature DB >> 15253986

Renal dysfunction and acceleration of coronary disease.

M W Yerkey1, S J Kernis, B A Franklin, K R Sandberg, P A McCullough.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15253986      PMCID： PMC1768370          DOI： 10.1136/hrt.2003.015503

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  19 in total

Review 1.  Epidemiology of cardiovascular disease in chronic renal disease.

Authors:  R N Foley; P S Parfrey; M J Sarnak
Journal:  J Am Soc Nephrol       Date:  1998-12       Impact factor: 10.121

2.  Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients.

Authors:  Sergio Stefoni; Giuseppe Cianciolo; Gabriele Donati; Ada Dormi; Maria Grazia Silvestri; Luigi Colì; Antonio De Pascalis; Sandra Iannelli
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

3.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.

Authors:  W G Goodman; J Goldin; B D Kuizon; C Yoon; B Gales; D Sider; Y Wang; J Chung; A Emerick; L Greaser; R M Elashoff; I B Salusky
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

4.  The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions.

Authors:  Patricia J M Best; Ryan Lennon; Henry H Ting; Malcolm R Bell; Charanjit S Rihal; David R Holmes; Peter B Berger
Journal:  J Am Coll Cardiol       Date:  2002-04-03       Impact factor: 24.094

5.  Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction.

Authors:  J N Beattie; S S Soman; K R Sandberg; J Yee; S Borzak; M Garg; P A McCullough
Journal:  Am J Kidney Dis       Date:  2001-06       Impact factor: 8.860

6.  Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease.

Authors:  B J Manns; E D Burgess; M E Hyndman; H G Parsons; J P Schaefer; N W Scott-Douglas
Journal:  Am J Kidney Dis       Date:  1999-10       Impact factor: 8.860

7.  Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk.

Authors:  Atul Aggarwal; Samer S Kabbani; Jeffery M Rimmer; F John Gennari; Douglas J Taatjes; Burton E Sobel; David J Schneider
Journal:  Am J Kidney Dis       Date:  2002-08       Impact factor: 8.860

Review 8.  Cardiorenal risk: an important clinical intersection.

Authors:  Peter A McCullough
Journal:  Rev Cardiovasc Med       Date:  2002       Impact factor: 2.930

9.  Acute myocardial infarction and renal dysfunction: a high-risk combination.

Authors:  R Scott Wright; Guy S Reeder; Charles A Herzog; Robert C Albright; Brent A Williams; David L Dvorak; Wayne L Miller; Joseph G Murphy; Stephen L Kopecky; Allan S Jaffe
Journal:  Ann Intern Med       Date:  2002-10-01       Impact factor: 25.391

10.  Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.

Authors:  Glenn M Chertow; Steven K Burke; Paolo Raggi
Journal:  Kidney Int       Date:  2002-07       Impact factor: 10.612
View more
  16 in total

1.  Lipoprotein subfractions and particle size in end-stage renal disease.

Authors:  Peter A McCullough; Fawaz Al-Ejel; Robert C Maynard
Journal:  Clin J Am Soc Nephrol       Date:  2011-12       Impact factor: 8.237

2.  Cardiorenal syndromes.

Authors:  Peter A McCullough; Aftab Ahmad
Journal:  World J Cardiol       Date:  2011-01-26

3.  Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD.

Authors:  Anjali Ganda; Laurent Yvan-Charvet; Yuan Zhang; Eric J Lai; Renu Regunathan-Shenk; Farah N Hussain; Rupali Avasare; Bibhas Chakraborty; Annie J Febus; Linda Vernocchi; Rafael Lantigua; Ying Wang; Xu Shi; Joanne Hsieh; Andrew J Murphy; Nan Wang; Nora Bijl; Kristie M Gordon; Maria Hamm de Miguel; Jessica R Singer; Jonathan Hogan; Serge Cremers; Martin Magnusson; Olle Melander; Robert E Gerszten; Alan R Tall
Journal:  J Mol Cell Cardiol       Date:  2017-05-04       Impact factor: 5.000

Review 4.  Epidemiology and outcome of the cardio-renal syndrome.

Authors:  Dinna N Cruz; Mihai Gheorghiade; Alberto Palazzuoli; Alberto Palazuolli; Claudio Ronco; Sean M Bagshaw
Journal:  Heart Fail Rev       Date:  2011-11       Impact factor: 4.214

5.  Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function.

Authors:  Peter A McCullough; Denise Barnard; Robert Clare; Stephen J Ellis; Jerome L Fleg; Gregg C Fonarow; Barry A Franklin; Ryan D Kilpatrick; Dalane W Kitzman; Christopher M O'Connor; Ileana L Piña; Udho Thadani; Vinay Thohan; David J Whellan
Journal:  Clin Cardiol       Date:  2013-08-08       Impact factor: 2.882

Review 6.  Applications and Limitations of Mouse Models for Understanding Human Atherosclerosis.

Authors:  Moritz von Scheidt; Yuqi Zhao; Zeyneb Kurt; Calvin Pan; Lingyao Zeng; Xia Yang; Heribert Schunkert; Aldons J Lusis
Journal:  Cell Metab       Date:  2016-12-01       Impact factor: 27.287

Review 7.  Statin therapy in renal disease: harmful or protective?

Authors:  Peter A McCullough; Leslie R Rocher
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

8.  Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis.

Authors:  Anjali Ganda; Martin Magnusson; Laurent Yvan-Charvet; Bo Hedblad; Gunnar Engström; Ding Ai; Thomas J Wang; Robert E Gerszten; Olle Melander; Alan R Tall
Journal:  Circulation       Date:  2013-02-01       Impact factor: 29.690

9.  Assessment and modeling of routinely used biochemical laboratory data of healthy individuals and end-stage renal failure (ESRF) patients by three different chemometric methods.

Authors:  Agelos Papaioannou; George Rigas; Panagiotis Plageras; George A Karikas; George Karamanis
Journal:  J Clin Lab Anal       Date:  2013-05       Impact factor: 2.352

10.  Statin therapy in renal disease: harmful or protective?

Authors:  Peter A McCullough; Leslie R Rocher
Journal:  Curr Diab Rep       Date:  2007-12       Impact factor: 4.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.